Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ETT Completes First-in-Human Cases With its Endomina Triangulation Platform

Published: Friday, October 05, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Results confirm the safety and efficacy of the device and will lead to an extended clinical trial in 2013 at four key centers in Europe.

Endo Tools Therapeutics has announced the completion of several first-in-human cases where Endo Tools' new Endomina™ triangulation platform has been used.

Endomina is a universal platform that adds triangulation to any endoscope and that can be used with any endoscopic tool available for gastro-enterologists. It allows the surgeons to perform complex movements and to use multiple tools.

Dr Vincent Huberty and Dr Mostafa Ibrahim, both from Erasme hospital in Brussels, Belgium, first used Endomina to perform complex tissue resection and anterior-posterior tissue apposition in various models.

The device was then used on four patients in April, May, July and September 2012. The first two patients showed the safety of the device and highlighted the differences between all models done previously and real patients.

For the two other patients, the team, led by Prof. Jacques Deviere, chairman of the department of gastroenterology, was able to perform a full-thickness suture in the stomach, showing its potential for pouch reduction.

It allowed the surgeons to perform all the acts and validate the functionality of the device. All patients were released after a maximum of two days.

Endomina is an innovative device that adds multiple degrees of freedom and therapeutic channels to a conventional endoscope, a device that allows surgeons to look inside the body.

It gives full freedom to gastro-enterologists to perform manipulations that were until now only possible through laparoscopic access, often referred to as "keyhole surgery".

The devices open new opportunities for advances in flexible endoscopy, and for treatment of major diseases such as obesity, type II diabetes or gastro-intestinal tract tumors.

For the patient, the use of Endomina induces reduced hospitalization and improved comfort, due to lower anesthesia requirement. For hospitals and social security systems, it means a reduced overall intervention cost.

"For years, therapeutic endoscopists have been one-armed surgeons. Endomina offers the opportunity to work with two hands and therefore to do simple things like lifting tissue or making a knot, which have not been possible up to now," said Prof. Jacques Deviere, chairman of the department of gastroenterology. "I think it is a first step towards real endoluminal surgery."

The Erasme clinical trial, focused on morbid obesity treatment, will soon be expanded to four other key centers in Europe with a target of 50 patients in 2013.

To treat morbid obesity, surgeons usually perform a restrictive surgery of the stomach. There are more than 200,000 such procedures per year in the EU, representing a market of EUR two billion.

"The initial feedback about Endomina has been outstanding and many key clinicians who have been introduced to our technology are excited about its potential for new endoluminal surgery," said Alexandre Chau CEO of Endo Tools Therapeutics.

Chau continued, "We are in the process of raising funds to get to the next step of our development and put the device on the market in the EU."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Endo Tools Therapeutics Secures EUR 2.5 Million in Second Round Funding
The investment provides Endo Tools Therapeutics with funding for clinical trials in obesity treatment, to take place in 2013 and 2014.
Wednesday, September 11, 2013
Scientific News
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Benefits of Early Antiretroviral Therapy in HIV Infection
Scientists have explored the clinical importance of starting treatment early in individuals suffering with HIV.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!